Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients

Phase 2RecruitingNCT06863376

Tanta University46 enrolled

Overview

Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. Lifestyle interventions, including dietary modification and exercise, remain the cornerstone of NAFLD treatment. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Non-Alcoholic Fatty Liver Disease

Interventions

Carbocysteine 375 MG

Physical activity, walking, and calorie restrictionOTHER

• The standard conventional therapy in both groups included regular exercise in the form of any physical activity as walking, cycling, etc. for 30-45 minutes minimum 5 days per week in addition to calorie restriction in overweight and obese patients

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Either male or female adult patients (\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography Exclusion Criteria: * Pregnant and/or lactating women * Excessive alcohol use (defined as an average alcohol intake \> 30 g per day in men and \> 20 g per day in women) * Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, autoimmune hepatitis. * patients suffering from chronic kidney disease, and hyper/hypoparathyroidism * Hypersensitivity to carbocistiene.

Outcomes

Primary Outcomes

The change in the degree of steatosis in the Ultra Sound

Time frame: 3 months